PittsburghV1, Ncbi, Curation, bibRecord, 004051

Tumor antigen-specific monoclonal antibodies and induction of T cell immunity

Identifieur interne : 004051 ( Ncbi/Curation ); précédent : 004050; suivant : 004052

Tumor antigen-specific monoclonal antibodies and induction of T cell immunity

Auteurs : Sumita Trivedi [États-Unis] ; H-B Jie [États-Unis] ; Robert L. Ferris [États-Unis]

Source :

Seminars in oncology [ 0093-7754 ] ; 2014.

RBID : PMC:4254440

Descripteurs français

KwdFr :
- Animaux, Anticorps monoclonaux (immunologie), Anticorps monoclonaux (usage thérapeutique), Antigènes néoplasiques (immunologie), Humains, Lymphocytes T (immunologie), Tumeurs (), Tumeurs (immunologie).
MESH :
- immunologie : Anticorps monoclonaux, Antigènes néoplasiques, Lymphocytes T, Tumeurs.
- usage thérapeutique : Anticorps monoclonaux.
- Animaux, Humains, Tumeurs.

English descriptors

KwdEn :
- Animals, Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (therapeutic use), Antigens, Neoplasm (immunology), Humans, Neoplasms (immunology), Neoplasms (therapy), T-Lymphocytes (immunology).
MESH :
- chemical , immunology : Antibodies, Monoclonal, Antigens, Neoplasm.
- chemical , therapeutic use : Antibodies, Monoclonal.
- immunology : Neoplasms, T-Lymphocytes.
- therapy : Neoplasms.
- Animals, Humans.

Abstract

For decades the primary available cancer therapies were relatively nonspecific cytotoxic agents which, while effective in some patients, were limited by narrow therapeutic indices, extensive toxicity and development of resistance, likely due to tumor heterogeneity. Although these chemotherapies remain common tools of conventional treatment, the approval of a growing number of tumor antigen (TA) specific monoclonal antibodies (mAb) by the FDA, has driven a shift in the paradigm of cancer therapy. For a subset of patients with lymphoma, colorectal, head and neck and breast cancer, the inclusion of rituximab (anti-CD20), cetuximab (anti–human epidermal growth factor 1), and trastuzumab (anti–human epidermal growth factor2 ) has resulted in overall improved clinical response rates and survival advantages. The mechanisms which contribute to these effects are not only limited to inhibition of signaling pathways, but also by cell-mediated cytotoxicity by innate immune cells and priming of effector cells of adoptive immunity triggered by the TA-specific mAb. As the use of these therapeutic mAb has become more widespread, however, it has been observed that there is significant variability of response in patients who have received treatment with these agents. Thus, the factors which mediate this variability in clinical response of the treated patients must be elucidated, in order to optimize the use of TA-specific mAb.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254440

DOI: 10.1053/j.seminoncol.2014.08.003
PubMed: 25440612
PubMed Central: 4254440

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F44
to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000F19
to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000165
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001547
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001541
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001541
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004051

Links to Exploration step

PMC:4254440

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor antigen-specific monoclonal antibodies and induction of T cell immunity</title>
<author><name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jie, H B" sort="Jie, H B" uniqKey="Jie H" first="H-B" last="Jie">H-B Jie</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A2">Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A3">Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">25440612</idno>
<idno type="pmc">4254440</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4254440</idno>
<idno type="RBID">PMC:4254440</idno>
<idno type="doi">10.1053/j.seminoncol.2014.08.003</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">000F44</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000F44</idno>
<idno type="wicri:Area/Pmc/Curation">000F19</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F19</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000165</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000165</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001547</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001547</idno>
<idno type="wicri:Area/PubMed/Curation">001541</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001541</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001541</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001541</idno>
<idno type="wicri:Area/Ncbi/Merge">004051</idno>
<idno type="wicri:Area/Ncbi/Curation">004051</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Tumor antigen-specific monoclonal antibodies and induction of T cell immunity</title>
<author><name sortKey="Trivedi, Sumita" sort="Trivedi, Sumita" uniqKey="Trivedi S" first="Sumita" last="Trivedi">Sumita Trivedi</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jie, H B" sort="Jie, H B" uniqKey="Jie H" first="H-B" last="Jie">H-B Jie</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ferris, Robert L" sort="Ferris, Robert L" uniqKey="Ferris R" first="Robert L." last="Ferris">Robert L. Ferris</name>
<affiliation wicri:level="3"><nlm:aff id="A1">Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A2">Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:aff id="A3">Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh, USA</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Cancer Immunology Program, University of Pittsburgh Cancer Institute, Pittsburgh</wicri:regionArea>
<placeName><settlement type="city">Pittsburgh</settlement>
<region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Seminars in oncology</title>
<idno type="ISSN">0093-7754</idno>
<idno type="eISSN">1532-8708</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Monoclonal (immunology)</term>
<term>Antibodies, Monoclonal (therapeutic use)</term>
<term>Antigens, Neoplasm (immunology)</term>
<term>Humans</term>
<term>Neoplasms (immunology)</term>
<term>Neoplasms (therapy)</term>
<term>T-Lymphocytes (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps monoclonaux (immunologie)</term>
<term>Anticorps monoclonaux (usage thérapeutique)</term>
<term>Antigènes néoplasiques (immunologie)</term>
<term>Humains</term>
<term>Lymphocytes T (immunologie)</term>
<term>Tumeurs ()</term>
<term>Tumeurs (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term>
<term>Antigens, Neoplasm</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps monoclonaux</term>
<term>Antigènes néoplasiques</term>
<term>Lymphocytes T</term>
<term>Tumeurs</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Neoplasms</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Tumeurs</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">For decades the primary available cancer therapies were relatively nonspecific cytotoxic agents which, while effective in some patients, were limited by narrow therapeutic indices, extensive toxicity and development of resistance, likely due to tumor heterogeneity. Although these chemotherapies remain common tools of conventional treatment, the approval of a growing number of tumor antigen (TA) specific monoclonal antibodies (mAb) by the FDA, has driven a shift in the paradigm of cancer therapy. For a subset of patients with lymphoma, colorectal, head and neck and breast cancer, the inclusion of rituximab (anti-CD20), cetuximab (anti–human epidermal growth factor 1), and trastuzumab (anti–human epidermal growth factor2 ) has resulted in overall improved clinical response rates and survival advantages. The mechanisms which contribute to these effects are not only limited to inhibition of signaling pathways, but also by cell-mediated cytotoxicity by innate immune cells and priming of effector cells of adoptive immunity triggered by the TA-specific mAb. As the use of these therapeutic mAb has become more widespread, however, it has been observed that there is significant variability of response in patients who have received treatment with these agents. Thus, the factors which mediate this variability in clinical response of the treated patients must be elucidated, in order to optimize the use of TA-specific mAb.</p>
</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Ncbi/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004051 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004051 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:4254440
   |texte=   Tumor antigen-specific monoclonal antibodies and induction of T cell immunity
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:25440612" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Tumor antigen-specific monoclonal antibodies and induction of T cell immunity

Tumor antigen-specific monoclonal antibodies and induction of T cell immunity

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki